Platelet-rich plasma: Myth or reality?

Martínez, A; Ruiz-Santiago, F.; García-Espinosa, J.

doi:10.1016/j.rxeng.2018.08.001

Cited by 23 publications

(26 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another important point to take into account is the different ways to prepare PRP. Indeed, there are different recipes to prepare a platelet concentrate, such as platelet‐rich plasma with leukocytes or not, autologous conditioned serum (ACS), plasma rich in growth factors (PRGF) or plasma rich fibrin (PRF) (Martínez‐Martínez et al., 2018). However, the general principle remains the same, with platelet‐rich plasma allowing the release of large quantities of growth factors.…”

Section: Platelet‐rich Plasma and Neuropathic Painmentioning

confidence: 99%

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Bohren

Timbolschi

Müller

et al. 2021

European Journal of Pain

View full text Add to dashboard Cite

Background and Objective Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory system. A number of preclinical studies have provided evidence for the involvement of cytokines, predominantly secreted by a variety of immune cells and by glial cells from the nervous system, in neuropathic pain conditions. Clinical trials and the use of anti‐cytokine drugs in different neuropathic aetiologies support the relevance of cytokines as treatment targets. However, the use of such drugs, in particularly biotherapies, can provoke notable adverse effects. Moreover, it is challenging to select one given cytokine as a target, among the various neuropathic pain conditions. It could thus be of interest to target other proteins, such as growth factors, in order to act more widely on the neuroinflammation network. Thus, platelet‐rich plasma (PRP), an autologous blood concentrate, is known to contain a natural concentration of growth factors and immune system messengers and is widely used in the clinical setting for tissue regeneration and repair. Database and Data Treatment In the present review, we critically assess the current knowledge on cytokines in neuropathic pain by taking into consideration both human studies and animal models. Results This analysis of the literature highlights the pathophysiological importance of cytokines. We particularly highlight the concept of time‐ and tissue‐dependent cytokine activation during neuropathic pain conditions. Conclusion Thus, direct or indirect cytokines modulation with biotherapies or growth factors appears relevant. In addition, we discuss the therapeutic potential of localized injection of PRP as neuropathic pain treatment by pointing out the possible link between cytokines and the action of PRP. Significance Preclinical and clinical studies highlight the idea of a cytokine imbalance in the development and maintenance of neuropathic pain. Clinical trials with anticytokine drugs are encouraging but are limited by a 'cytokine candidate approach' and adverse effect of biotherapies. PRP, containing various growth factors, is a new therapeutic used in regenerative medicine. Growth factors can be also considered as modulators of cytokine balance. Here, we emphasize a potential therapeutic effect of PRP on cytokine imbalance in neuropathic pain. We also underline the clinical interest of the use of PRP, not only for its therapeutic effect but also for its safety of use.

show abstract

Section: Platelet‐rich Plasma and Neuropathic Painmentioning

confidence: 99%

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Bohren

Timbolschi

Müller

et al. 2021

European Journal of Pain

View full text Add to dashboard Cite

show abstract

“…Platelet-rich plasma (PRP), a platelet concentrate extracted from autologous blood by centrifugation, was originally used in the clinic to improve hemostasis [5]. Upon activation, PRP releases a large number of growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), insulin-like growth factor (IGF), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), which plays a crucial role in bone regeneration due to its potential to repair tendons, ligaments, skeletal muscles and cartilage [6,7]. Among the methods, thrombin is a common and widely used approach to activate PRP.…”

Section: Introductionmentioning

confidence: 99%

Thrombin-activated platelet-rich plasma enhances osteogenic differentiation of human periodontal ligament stem cells by activating SIRT1-mediated autophagy

Wang

Liu

et al. 2021

Eur J Med Res

View full text Add to dashboard Cite

Background Platelet-rich plasma (PRP) has the potential to be used for bone regeneration. However, its effect on osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) and its effect on cell autophagy of hPDLSCs remain unknown. In this study, we investigated the effects of PRP on cell viability and osteogenic differentiation of hPDLSCs and the underlying molecular mechanisms. Methods hPDLSCs were isolated and identified by morphology and flow cytometry analysis. Next, thrombin-activated PRP was used to stimulate hPDLSCs. The MTT assay was used to analyze cell viability. Osteogenic differentiation was investigated using alkaline phosphatase (ALP) activity assay, alizarin red S (ARS) staining, and gene expression analysis of osteogenic markers. Expression of the autophagic proteins was determined using western blotting. Results Thrombin-activated PRP significantly enhanced cell viability, ALP activity, osteogenic-related mRNA levels and alizarin red-mineralization activity in hPDLSCs in a dose-dependent manner. Furthermore, activated PRP dose-dependently increased LC3-II/I ratio and the expression of SIRT1 and Beclin-1. PRP treatment also enhanced the autophagic flux. It was also demonstrated that the inhibition of SIRT1 using sirtinol or suppression of autophagy by 3-methyladenine (3-MA) abrogated PRP-induced viability and osteogenic differentiation of hPDLSCs. Conclusion Our study suggested that thrombin-activated PRP accelerated the viability and osteogenic differentiation of hPDLSCs via SIRT1-mediated autophagy induction.

show abstract

“…The bioactive materials in platelets are an admixture of pro-angiogenic, anti-angiogenic, and chemotactic factor which undergo degranulation and induce cellular proliferation, chondrogenesis, angiogenesis, and rejuvenation of degenerated tendons and fascia. 14,15 The results of using autologous platelet-rich plasma to treat chronic plantar fasciitis have been very encouraging but there is a dearth of literature comparing its effectiveness with steroid injection in long term for the treatment of chronic plantar fasciitis. 16 This prospective comparative study is conducted to compare the efficacy of the plateletrich plasma over local injection of corticosteroid.…”

Section: Introductionmentioning

confidence: 99%

Is platelet rich plasma superior to corticosteroid injection for recalcitrant plantar fasciitis? Results of a prospective comparative study

Somasundaram¹,

Pst²,

Muthu³

2021

IJOR

View full text Add to dashboard Cite

is one of the commonest causes of heel pain and can be very challenging for clinicians to treat it successfully in the long run. The results of using autologous platelet-rich plasma(PRP) to treat chronic plantar fasciitis have been very encouraging but there is a dearth of literature comparing its effectiveness with steroid injection in long term for the treatment of chronic plantar fasciitis. This prospective comparative study is conducted to compare the efficacy of PRP over corticosteroids. Materials and Methods: We conducted this prospective comparative study between PRP and steroid injection by enrolling patients who failed the conservative line of management for 6 weeks period. We sequentially followed up the patient at discharge from the hospital, 6 weeks, 3 months, 6 months, and one year. The preoperative and postoperative function was assessed with The American Orthopaedic Foot and Ankle SocietyAOFAS) Score including pain, function, alignment components along with the Visual Analog Scale(VAS) score for pain. Inter and Intragroup comparisons were made with student t-test and paired t-test respectively. Results: 50 patients with a mean age of 37.2 years were enrolled in the study. In comparison, the PRP group showed a significant improvement in the AOFAS score at 6 months (p=0.021) and 1 year(p=0.001) compared to the corticosteroid injection. However, the reduction in pain by the VAS score was comparable between the two groups at 6 months (p=0.542) and one year (p=0.224) respectively. Conclusion: While both PRP and corticosteroid injection significantly reduces the pain at 1-year followup, functional improvement is significantly better in the PRP group compared to the steroids. PRP injection therapy remains more effective compared to steroid injection in the management of recalcitrant plantar fasciitis considering the degenerative component of the disease entity.

show abstract

Platelet-rich plasma: Myth or reality?

Cited by 23 publications

References 67 publications

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Thrombin-activated platelet-rich plasma enhances osteogenic differentiation of human periodontal ligament stem cells by activating SIRT1-mediated autophagy

Is platelet rich plasma superior to corticosteroid injection for recalcitrant plantar fasciitis? Results of a prospective comparative study

Contact Info

Product

Resources

About